Brexanolone produces ‘meaningful reductions’ in postpartum depression
October 04, 2018
Most women who received an injection of brexanolone — a positive allosteric modulator of -aminobutyric-acid type A receptors — for postpartum depression had significant and clinically meaningful reductions of the condition at 60 hours vs. placebo, according to findings recently published in The Lancet.
READ FULL ARTICLE ON HELIO.COM